Generic filters
Filter by content type
Taxonomy terms

SMMT – Summit Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 1

Company Profile

Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company’s preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan